Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
MAGI1, also known as brain angiogenesis inhibitor associated protein 1 (BAP1), has three subtypes, MAGI1a, MAGI1b and MAGI1c, which are composed of 1139, 1171 and 1374 amino acid residues, respectively. There are also certain tissue expression and intracellular distribution specificity between different subtypes of MAGI1. MAGI1a and MAGI1c are mainly expressed in brain cells, while MAGI1b is mainly expressed in epithelial cells. MAGI1a and MAGI1b are mainly distributed in the cell membrane, and a small amount is distributed in the cytoplasm; while MAGI1c is mainly distributed in the nucleus due to its three-terminal nuclear localization sequence at the carboxy terminus.
MAGI1 showed a certain level of expression in both epithelial cells and nerve cells. Like other family members, MAGI1 consists of 5 to 6 PDZ domains, 2 WW domains, and 1 GK domain. The interaction of MAGI1 with PTEN is mediated by its PDZ2 domain.
MAGI1 and Tumor
MAGI1 is widely expressed in a variety of human tissues of almost all epithelial cell types, particularly in the human brain. Abnormal expression of MAGI1 is expressed in some cancer and human papillomavirus (HPV)-related diseases, but reports are rare. Studies have shown that in the study of the correlation between MAGI1 and malignant tumors, the down-regulation of MAGI1 activates the hippo downstream target protein YAP, which further confirms that the MAGI family may exert its anti-cancer effect by inhibiting the Hippo tumor signaling pathway.

Figure 1. A complex of MEK1, MAGI1, and PTEN regulates PIP3 turnover and AKT signaling (Zmajkovicova, et al. 2013)
MAGI1 and Colorectal Cancer
Studies have shown that immunofluorescence experiments in the colorectal cancer cell lines SW480 and HCT116 confirmed that up-regulation of MAGI1 can recruit PTEN, E-cadherin and β-catenin to the cell junction. On the one hand, it enhanced the formation of tension fibers and local adhesion plaques, which made the cell morphology flat. On the other hand, Wnt signaling pathway is down-regulated by lowering the expression level of beta-catenin in the cytoplasm, ultimately inhibiting the migration and invasion of colorectal cancer cells.
MAGI1 and Liver Cancer
In the analysis of gene expression profiles of liver cancer patients in Egypt, it was found that the expression level of MAGI1 in liver cancer patients was significantly lower than that in normal people. The results of clinical pathology showed that the expression level of MAGI1 not only has a low expression characteristic in liver cancer, but also has a certain correlation with the clinical stage of liver cancer. That is, patients with low expression of MAGI1 usually have a poor clinical stage and a short median survival time. Based on this clinical result, the researchers established a model of overexpression of the MAGI1 hepatocarcinoma cell line in the hepatocellular carcinoma cell line HepG2 for its malignant biological function experiments and molecular biological mechanisms. The results showed that overexpression of MAGI1 significantly reduced the migration and invasion of HepG2 cells, and significantly up-regulated the expression of PTEN, suggesting that MAGI1 may inhibit the invasion and migration of hepatoma cells by regulating PTEN.
MAGI1 and Cervical Cancer
Studies have found that in ZO-1 as a marker of tight junctional integrity, a tight junction loss in HPV-positive cervical cancer cells was observed with a decrease in MAGI1 expression. When the HPV E6 protein expression was inhibited, MAGI1 accumulated at the cell membrane, and zo-1 reunited, indicating a tightly connected repair. This experiment suggests that MAGI1 may be one of the HPV E6 proteins targeting recognition proteins in cervical cancer cells, and MAGI1 not only helps maintain the stability of cell junctions and cell-to-cell communication, but also induces apoptosis in polar epithelial cells. Therefore, specific mediated MAGI1 degradation may be one of the important processes in HPV infection.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.